Patent classifications
C07D239/14
META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS
The present disclosure provides pharmaceutical agents of the formula:
##STR00001##
wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.
META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS
The present disclosure provides pharmaceutical agents of the formula:
##STR00001##
wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.
TETRALIN AND INDANE DERIVATIVES AND USES THEREOF
The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.
##STR00001##
TETRALIN AND INDANE DERIVATIVES AND USES THEREOF
The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.
##STR00001##
Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
The present disclosure provides pharmaceutical agents of the formula: ##STR00001##
wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.
Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
The present disclosure provides pharmaceutical agents of the formula: ##STR00001##
wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.
SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof wherein in, R.sup.1, R.sup.2, R.sup.3, L and X are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy particularly for use in treating disorders associated with nicotinic acetylcholine receptor 6 (nAChR6) activity.
##STR00001##
INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF
This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF
This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof
The invention relates to the novel products of formula (I):
##STR00001##
with p, q=0, 1 or 2; R1=phenyl, pyridyl; (CH.sub.2).sub.mRa; alkylene; cycloalkyl; heterocycloalkyl; alkyl; SO.sub.2Rb; CORe; m=1 or 2; Ra=aryl, heteroaryl, CO-cycloalkyl, CO-heterocycloalkyl, CORb, C(Rb)NORc, CO.sub.2Rd, CONRxRy; Rb=alkyl, aryl, heteroaryl; Rc=H, alkyl; Rd=alkyl, cycloalkyl; Re=alkyl, cycloalkyl, aryl, heteroaryl; NRxRy with Rx,Ry=H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3=H, alkyl, CF.sub.3, or form with C a ring with optionally O, S and N; R4=H, F, Cl, CH.sub.3 or CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is
##STR00002##
and the isomer of configuration R,R
##STR00003##
these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments.